Table 1.
List of available biomarkers used in immuno-diagnostic assays to predict the response to immunotherapy in cancer patients. For each assay, a description of the technology used, its type, and status are provided. Abbreviations: MSI: Microsatellite instability, PD-L1: Programmed cell Death-Ligand 1, TILs: Tumor Infiltrating lymphocytes, Tis: Tumor infiltration signature, TLS: Tertiary Lymphoid structures, TMB: Tumor mutational burden, IHC: Immunohistochemistry, CDx: Companion Diagnostics, RUO: Research use only.
| Assays | technology | Type | Status |
|---|---|---|---|
| MSI | IHC/genomic | Qualitative | CDx approved |
| TMB | ExomeSeq | Quantitative | CDx approved |
| PD-L1 | IHC | Semi- quantitative | CDx approved |
| Immunoscore-IC | digital pathology | Quantitative | RUO |
| Immunoscore | digital pathology | Quantitative | RUO |
| TILs | IHC | Semi- quantitative | RUO |
| Tis | Gene expression | Quantitative | RUO |
| TLS | IHC | Qualitative | RUO |
| Multiplex IHC | digital pathology | Quantitative | RUO |